Cerebrolysin Attenuates Heat Shock Protein (HSP 72 KD) Expression in the Rat Spinal Cord Following Morphine Dependence and Withdrawal: Possible New Therapy for Pain Management.

Sharma HS, Ali SF, Patnaik R, Zimmermann-Meinzingen S, Sharma A, Muresanu DF

Current neuropharmacology1 Mar 2011Cited by 23 (Europe PMC)

PMID21886595PMCIDPMC3137188DOI10.2174/157015911795017100PepBankPUB-21886595

Summary

The possibility that pain perception and processing in the CNS results in cellular stress and may influence heat shock protein (HSP) expression was examined in a rat model of morphine dependence and withdrawal. Since activation of pain pathways result in exhaustion of growth factors, we examined the influence of cerebrolysin, a mixture of potent growth factors (BDNF, GDNF, NGF, CNTF etc,) on morphine induced HSP expression. Rats were administered morphine (10 mg/kg, s.c. /day) for 12 days and the spontaneous withdrawal symptoms were developed by cessation of the drug administration on day 13(th) that were prominent on day 14(th) and continued up to day 15(th) (24 to 72 h periods). In a separate group of rats, cerebrolysin was infused intravenously (5 ml/kg) once daily from day one until day 15(th). In these animals, morphine dependence and withdrawal along with HSP immunoreactivity was examined using standard protocol. In untreated group mild HSP immunoreaction was observed during morphine tolerance, whereas massive upregulation of HSP was seen in CNS during withdrawal phase that correlated well with the withdrawal symptoms and neuronal damage. Pretreatment with cerebrolysin did not affect morphine tolerance but reduced the HSP expression during this phase. Furthermore, cerebrolysin reduced the withdrawal symptoms on day 14(th) to 15(th). Taken together these observations suggest that cellular stress plays an important role in morphine induced pain pathology and exogenous supplement of growth factors, i.e. cerebrolysin attenuates HSP expression in the CNS and induce neuroprotection. This indicates a new therapeutic role of cerebrolysin in the pathophysiology of drugs of abuse, not reported earlier.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, Cerebrolysin pretreatment did not affect morphine tolerance compared with untreated animals.
In plain wordsIn rats, Cerebrolysin did not change morphine tolerance compared with untreated animals.
Peptide
Cerebrolysin
Outcome
No significant changeMorphine tolerance
Study
ratn: not reported in source
Morphine dependence and withdrawal
Comparator
Untreated group
Outcome group
Addiction, withdrawal and alcohol intake · Nervous system and cognition
Studied dose
5 ml/kg · intravenously · from day one until day 15(th)As given in this study (rat).
Source sentences
Summary
Pretreatment with cerebrolysin did not affect morphine tolerance but reduced the HSP expression during this phase.
1 context sentence(design, population, supporting numbers)
Summary · context
In a separate group of rats, cerebrolysin was infused intravenously (5 ml/kg) once daily from day one until day 15(th).
Show in the study text Report a problemFND-2188659501
02AnimalAnimal study (in vivo)Mechanism
In rats, Cerebrolysin pretreatment reduced HSP expression during morphine tolerance compared with untreated animals.
In plain wordsIn rats, Cerebrolysin reduced HSP expression during morphine tolerance compared with untreated animals.
Peptide
Cerebrolysin
Outcome
DecreaseHSP expression during tolerance
Study
ratn: not reported in source
Morphine dependence and withdrawal
Comparator
Untreated group
Outcome group
Gene expression · Nervous system and cognition
Studied dose
5 ml/kg · intravenously · from day one until day 15(th)As given in this study (rat).
Source sentences
Summary
Pretreatment with cerebrolysin did not affect morphine tolerance but reduced the HSP expression during this phase.
1 context sentence(design, population, supporting numbers)
Summary · context
In a separate group of rats, cerebrolysin was infused intravenously (5 ml/kg) once daily from day one until day 15(th).
Show in the study text Report a problemFND-2188659502
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, Cerebrolysin reduced withdrawal symptoms on day 14(th) to 15(th) compared with untreated animals.
In plain wordsIn rats, Cerebrolysin reduced morphine withdrawal symptoms compared with untreated animals.
Peptide
Cerebrolysin
Outcome
DecreaseWithdrawal symptoms
Study
ratn: not reported in source
Morphine dependence and withdrawal
Comparator
Untreated group
Outcome group
Addiction, withdrawal and alcohol intake · Nervous system and cognition
Studied dose
5 ml/kg · intravenously · from day one until day 15(th)As given in this study (rat).
Source sentences
Summary
Furthermore, cerebrolysin reduced the withdrawal symptoms on day 14(th) to 15(th).
1 context sentence(design, population, supporting numbers)
Summary · context
In a separate group of rats, cerebrolysin was infused intravenously (5 ml/kg) once daily from day one until day 15(th).
Show in the study text Report a problemFND-2188659503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with morphine dependence and withdrawal, the observations suggest that Cerebrolysin induced neuroprotection.
In plain wordsIn rats with morphine dependence and withdrawal, the observations suggest that Cerebrolysin protected nerve cells.
Peptide
Cerebrolysin
Outcome
IncreaseNeuroprotection
Study
ratn: not reported in source
Morphine dependence and withdrawal
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
5 ml/kg · intravenously · from day one until day 15(th)As given in this study (rat).
Source sentences
Summary
Taken together these observations suggest that cellular stress plays an important role in morphine induced pain pathology and exogenous supplement of growth factors, i.e. cerebrolysin attenuates HSP expression in the CNS and induce neuroprotection.
1 context sentence(design, population, supporting numbers)
Summary · context
In a separate group of rats, cerebrolysin was infused intravenously (5 ml/kg) once daily from day one until day 15(th).
Show in the study text Report a problemFND-2188659504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.